Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the rs4541843 G > A variant was found to be significantly associated with increased risk and severity of alopecia areata, as well as elevated expression of hsa-miR-182-5p, suggesting their potential as molecular markers for diagnosis and severity assessment.

This review found that laser-assisted drug delivery in humans was associated with several adverse effects, but no life-threatening events were reported in the studies examined.

In this study, researchers found that applying mometasone furoate 0.1% cream combined with adapalene 0.1% gel resulted in significantly greater hair regrowth over 12 weeks compared to mometasone furoate cream alone in patients with alopecia areata.

This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.

This study found that RCM combined with dermoscopy can differentiate disease states between alopecia areata, tinea capitis, nevus sebaceous, and linear scleroderma of the scalp by identifying distinct dermal and follicular patterns.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

A specific gene variant is linked to heart disease, increased heart muscle, curly hair, and thick skin on palms and soles.

This case study details the successful treatment of macrophage activation syndrome with dexamethasone and cyclosporine in a 36-year-old woman with adult-onset Still's disease, highlighting the critical importance of timely aggressive treatment.

This review discusses the use of dermal regeneration templates for treating burn injuries and other wounds, highlighting their effectiveness in reducing scars and aiding in regenerative processes, but reports no new clinical results.

This study found that metabolic syndrome was more prevalent among androgenetic alopecia patients than controls, with higher serum RANTES levels suggesting a potential role in the syndrome's pathogenesis.

This study found that a dopamine-methacrylated hyaluronic acid hydrogel enhances the efficacy of adipose-derived stem cells in promoting skin regeneration, potentially involving the Notch signaling pathway.

This editorial discusses the experiences and highlights of the Dermatology Nurses' Association's annual convention, including educational sessions about skin conditions and nursing strategies, and emphasizes the importance of continuing education and involvement in health policy and advocacy for dermatology nursing professionals.

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

This study found that a histochemical stain using 4-dimethyl-aminocinnamaldehyde effectively distinguishes between plucked anagen and telogen hairs by causing the root ends of anagen hairs to develop a red color.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This abstract reports on the 1997 meeting of the American Society of Hair Restoration Surgeons and the American Academy of Cosmetic Surgery, and it contains no new research findings.

In this study, researchers identified a recurrent nonsense mutation, c.409C>T (p.Arg137*), in the COL7A1 gene through whole exome sequencing in a family with autosomal recessive dystrophic epidermolysis bullosa, demonstrating the importance of this method for diagnosing genetically complex conditions.

In this study, the researchers found that after initial hair regrowth with ritlecitinib in patients with severe alopecia areata, it took a median of 93 days to reach clinical trial-defined scalp hair regrowth, with those responding earlier showing faster progression to desired outcomes.

This report describes the enhancement of the French SNIIRAM/SNDS healthcare database through external data linkages, highlighting its potential use in medical research despite complexities in the integration process.

This study found that a collaborative care model in rheumatoid arthritis clinics improved nb-DMARD dose optimization, adherence to monitoring guidelines, and detection of related adverse drug events compared to standard care.

In this observational study, dutasteride treatment was associated with statistically significant stabilization of frontal fibrosing alopecia compared to other systemic therapies, with a dose-dependent effect observed across the frontal and bilateral temporal hairlines.

This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.

Among participants in a 26-week trial, this study by REVIAN Inc. reported that their REVIAN RED dual wavelength LED light treatment for androgenetic alopecia was both safe and effective at the 16-week mark.

This case report highlights the rare overlap of DRESS and Stevens-Johnson syndrome following antituberculosis treatment, emphasizing the critical importance of timely diagnosis and intervention to manage severe symptoms and prevent organ damage.

This study found that the Transdermal Delivery System efficiently delivers testosterone systemically and showed bioequivalent hormone concentrations to a known topical gel in healthy males.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

This case report describes a rare aggressive variant of squamous cell carcinoma on the scalp of a non-immunosuppressed older male, highlighting its high biological risk for metastasis and poor outcomes.